https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-03-01 / Oncoimmunology 2013 Mar;2(3):e23401
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-03-01 / Oncoimmunology 2013 Mar;2(3):e234012013-03-01 00:00:002019-02-15 08:47:41The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-15 / Cancer Res. 2013 Apr;73(8):2493-504
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-15 / Cancer Res. 2013 Apr;73(8):2493-5042013-02-15 00:00:002019-02-15 08:39:50Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-11 / J. Clin. Oncol. 2013 Mar;31(8):1021-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-11 / J. Clin. Oncol. 2013 Mar;31(8):1021-82013-02-11 00:00:002019-02-15 08:35:16Harnessing the immune system for the treatment of non-small-cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / Hum Vaccin Immunother 2013 May;9(5):1069-722013-02-01 00:00:002024-08-26 09:28:16Current status of immunotherapy for the treatment of biliary tract cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / Immunotherapy 2013 Feb;5(2):155-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / Immunotherapy 2013 Feb;5(2):155-672013-02-01 00:00:002019-02-15 08:46:29Vaccine strategies for glioblastoma: progress and future directions
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / J. Immunother. 2013 Feb;36(2):152-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / J. Immunother. 2013 Feb;36(2):152-72013-02-01 00:00:002019-02-15 08:46:30Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-02-01 / BioDrugs 2013 Feb;27(1):35-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-02-01 / BioDrugs 2013 Feb;27(1):35-532013-02-01 00:00:002021-11-15 16:56:59Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-800
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-23 / J. Virol. 2013 Apr;87(7):3792-8002013-01-23 00:00:002013-01-23 00:00:00Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-10 / Transl Res 2013 Apr;161(4):355-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-10 / Transl Res 2013 Apr;161(4):355-642013-01-10 00:00:002019-02-15 09:22:40Oncolytic virus therapy for cancer: the first wave of translational clinical trials
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):56-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2013-01-10 / Biofactors 2013 Jan-Feb;39(1):56-682013-01-10 00:00:002013-01-10 00:00:00Curcumin in various cancers
